MAJI (Exousia Pro) Common Stock: $15.32 Mil (As of Jan. 2021)


What is Exousia Pro Common Stock?

Exousia Pro MAJI -18.45% Common Stock is $15.32 Mil as of Jan. 2021.

Exousia Pro's quarterly common stock increased from Jul. 2020 ($0.25 Mil) to Oct. 2020 ($0.28 Mil) and increased from Oct. 2020 ($0.28 Mil) to Jan. 2021 ($15.32 Mil).

Exousia Pro's annual common stock increased from Apr. 2012 ($0.11 Mil) to Apr. 2018 ($0.25 Mil) but then stayed the same from Apr. 2018 ($0.25 Mil) to Apr. 2019 ($0.25 Mil).

Exousia Pro Common Stock Historical Data

* Premium members only.

The historical data trend for Exousia Pro's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Exousia Pro Common Stock Chart

Exousia Pro Annual Data
Trend Apr11 Apr12 Apr18 Apr19
Common Stock
0.10 0.11 0.25 0.25

Exousia Pro Quarterly Data
Oct11 Jan12 Apr12 Jul12 Oct12 Jan13 Oct17 Jan18 Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.25 0.25 0.25 0.28 15.32

Exousia Pro Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of $15.32 Mil mean?
Exousia Pro (MAJI) has a Common Stock of $15.32 Mil as of Jan. 2021. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Exousia Pro and its competitors.
Is Exousia Pro's Common Stock too high?
Exousia Pro's current Common Stock is $15.32 Mil.
How does Exousia Pro's Common Stock compare to HCCH and GRNV?
Exousia Pro's Common Stock of $15.32 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Exousia Pro and its competitors. Exousia Pro's current Common Stock is $15.32 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Exousia Pro stock overvalued right now?
Exousia Pro (MAJI) has a current Common Stock of $15.32 Mil. The current Common Stock is $15.32 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Exousia Pro (MAJI), the current Common Stock is $15.32 Mil as of Jan. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Exousia Pro Business Description

Address 7901 4th Street North, No. 23494, St. Petersburg, FL, USA, 33702
Exousia Pro Inc is a exosome-based biotechnology, develops and manufactures mammalian and plant-based exosomes using proprietary technologies for nucleic acid loading and targeted delivery to tissues and cells. The company is developing new ways to exploit the therapeutic potential of exosomes, initially focused in the field of oncology. The platform technology of the company also helps treating a broad spectrum of viral infections.